News 2024-10-10
Connect with Porton J-STAR at AAPS PharmSci 360 2024 @ Booth 2431
The AAPS PharmSci 360, held from October 20-23, 2024, is an eminent event in the pharmaceutical industry, renowned for its convergence of key players, thought leaders, and innovative companies from across the globe. This year, Porton J-STAR invites you to connect with us at Booth 2431, where we will be exhibiting our end-to-end global CDMO service capabilities across both drug substance and drug product development and manufacturing, and the differentiated advantages these services offer to customers.
We employ advanced technologies and methodologies in our CDMO services. Our participation at AAPS PharmSci 360 reflects our dedication to innovation and excellence. With over 10,000 professionals and numerous exhibitors from various segments of the pharmaceutical industry, this conference is a premier platform for networking, collaboration, and showcasing cutting-edge advancements. It provides an unparalleled opportunity for us to engage with industry peers, explore potential partnerships, and drive forward the growth and innovation of the pharmaceutical sector.
As one of the world's leading CDMO companies, Porton J-STAR will be attending the event. Our expert speakers will deliver advanced technical insights and industry perspectives, offering attendees a deep dive into the latest developments.
For onsite meeting appointments, please contact:business@portonpharma.com.
Others
More
News 2025-01-14
Successful GMP Drug Product Delivery by Porton Biologics and Conjugates Platform
Recently, the Porton Biologics and Conjugates Platform successfully completed the GMP contract manufacturing of three batches of sterile drug products for a client at our R&D and production facility in Pudong, Shanghai. This milestone marks a significant step forward for our Biologics and Conjugates CDMO platform—a testament to our unwavering commitment to quality and reliability.
News 2025-01-03
Porton Achieves Higher Scores in the 2024 S & P Global ESG Assessment
Porton Pharma Solutions Ltd. (hereinafter “Porton”) is glad to announce that it scored 44 (out of 100) in the 2024 S&P Global Corporate Sustainability Assessment reflecting an improvement of 6 points over the previous assessment, where scores in all the three dimensions getting improved. (CSA Score as of 27/11/2024).
